News

Press Release

Go to Topics

Back number

2013

Sysmex Succeeds in World's First Practical Application of Technology Employing a Glycosylation Marker to Test Hepatic Fibrosis;
Technology Allows the Degree of Hepatic Fibrosis, from Hepatitis to Cirrhosis of the Liver, to Be Determined Swiftly
Sysmex Commences a Service (for Research) Involving Analysis of Genetic Expression in Breast Cancer Tissue
- Working toward Personalized Medicine for the Treatment of Breast Cancer -
XN-2000/XN Reagents in the Hematology Field Receive German Design Award
(Corrections and Corrections to Numerical Data) Partial Correction to Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2014 (PDF:257KB)
Sysmex Wins Awards in 2013 Local Commendation for Invention of Kinki
Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2014
*Revised on November 18, 2013 (PDF:154KB)
National Cancer Center and Sysmex Enter into Collaboration Agreement to Develop Cancer Diagnostic Reagents
- Promoting the Development of New Biomarkers -
Joint Establishment of Marketing Company with View to Developing Medical Robots
Insurance Coverage for Rapid Detection of Colorectal Cancer and Stomach Cancer Lymph Node Metastasis Based on the OSNA® Method
Sysmex Inostics and Bayer HealthCare collaborate to develop blood-based companion diagnostic tests for targeted tumor therapies
Sysmex Selected for Inclusion in the Asia Pacific Index of the Dow Jones Sustainability Indexes for Second Consecutive Year
Sysmex Acquiring Two Germany Based Companies to Expand its Technology Platform Targeting Personalized Medicine and Entering New Fields of Business
Details of Stock Options (Stock Acquisition Rights) to be allocated (PDF:82KB)
Concerning the Issuance of Stock Options (Stock Acquisition Rights) (PDF:61KB)
Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending March 31, 2014 (PDF:152KB)
Sysmex Establishes R&D Center Americas in the United States
- Accelerating the Globalization of our R&D Structure with the Aim of Realizing Personalized Medicine -
Sysmex Establishing New Instrument Factory to Meet Growing Global Demand
- Tripling Group Production Capacity by Simultaneously Expanding Sysmex and Affiliated Company Factories -
Sysmex Develops New Flag Technology for P. vivax and P. malariae
"Sysmex Forest" Established in Ono, Hyogo Prefecture
- Promoting Forest Conservation Activities Aimed at Making the Satoyama* a Place of Tranquility for People and Wildlife -
Consolidated Financial Results for the Year Ended March 31, 2013 (PDF:175KB)
Notice Regarding Dividends from Surplus (PDF:16KB)
Announcement of Executive Change (PDF:23KB)
Sysmex Announces New Group Mid-Term Management Plan
- Leveraging a Business Unit Structure to Accelerate Implementation Toward Achieving Long-Term Vision Objectives -
Sysmex Strengthens Sales and Support in South Korea
- Transitioning to a Direct Sales and Support Organization with a View to Further Growth in Hematology and Non-Hematology Fields -
Announcement Regarding Revision of Business Forecasts (PDF:66KB)
Sysmex Receives The Fiscal 2013 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology
(Corrections and Corrections to Numerical Data)Partial Correction to Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2013 (PDF:81KB)
Sysmex to Be Special Sponsor of the Kobe Marathon 2013
- We are pleased to have sponsored this exciting event since its inception in 2011 -
Announcement of Organizational and Personnel Changes
- Aiming to Accelerate Growth by Adopting a Structure Comprising Three Business Units - (PDF:109KB)
Sysmex Establishes Representative Office in Mongolia
Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2013 *Revised on March 22, 2013 (PDF:183KB)
XN-2000 and XN Reagents Win Germany’s iF Product Design Award 2013